Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
出版年份 2021 全文链接
标题
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
作者
关键词
-
出版物
ANNALS OF HEMATOLOGY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-12
DOI
10.1007/s00277-021-04447-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma
- (2020) Ravi Vij et al. CLINICAL CANCER RESEARCH
- Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry
- (2020) Maiia V. Firsova et al. BMC CANCER
- Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
- (2020) Xiang Zhou et al. Cancers
- CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
- (2020) Luis Gerardo Rodríguez-Lobato et al. Frontiers in Oncology
- CD319 ( SLAMF7 ) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab
- (2020) Kah Teong Soh et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Pomalidomide‐Dexamethasone for Treatment of Soft Tissue Plasmacytomas in Patients with relapsed / refractory Multiple Myeloma
- (2019) Raquel Jiménez‐Segura et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Extramedullary disease in multiple myeloma – controversies and future directions
- (2019) Sabina Sevcikova et al. BLOOD REVIEWS
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
- (2019) Eric L. Smith et al. Cancer Immunology Research
- Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone
- (2019) Satoko Oka et al. PATHOLOGY & ONCOLOGY RESEARCH
- Extramedullary multiple myeloma
- (2019) Manisha Bhutani et al. LEUKEMIA
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
- (2018) Meletios A. Dimopoulos et al. CANCER
- Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy
- (2018) Sophia Danhof et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features
- (2016) Leo Rasche et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- The possible perils of targeted therapy
- (2016) U Duffner et al. LEUKEMIA
- Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations
- (2015) Cindy Varga et al. BRITISH JOURNAL OF HAEMATOLOGY
- Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases
- (2015) Shuhui Deng et al. Clinical Lymphoma Myeloma & Leukemia
- Cytogenetics in multiple myeloma patients progressing into extramedullary disease
- (2015) Lenka Besse et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
- (2015) Lenka Besse et al. PLoS One
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Cytogenetics of extramedullary manifestations in multiple myeloma
- (2013) Lisa Billecke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases
- (2012) Leo Rasche et al. ANNALS OF HEMATOLOGY
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
- (2011) Alessandro Gozzetti et al. CANCER
- Eradication of Medullary Multiple Myeloma by CD4+ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen
- (2010) R. M. Spaapen et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started